JOHN KIRKWOOD to CD4-Positive T-Lymphocytes
This is a "connection" page, showing publications JOHN KIRKWOOD has written about CD4-Positive T-Lymphocytes.
Connection Strength
1.172
-
Cancer vaccine induces potent T cell responses - but is it enough? Nat Rev Clin Oncol. 2020 12; 17(12):721-722.
Score: 0.146
-
NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res. 2000 Sep 01; 60(17):4946-52.
Score: 0.143
-
Multiple antigen-engineered DC vaccines with or without IFNa to promote antitumor immunity in melanoma. J Immunother Cancer. 2019 04 24; 7(1):113.
Score: 0.130
-
Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1. J Immunol. 2011 Jan 01; 186(1):312-22.
Score: 0.073
-
Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines. J Immunother. 2010 Jul-Aug; 33(6):630-8.
Score: 0.071
-
Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res. 2009 Nov 15; 15(22):7036-44.
Score: 0.068
-
Cross-reactive CD4+ T cells against one immunodominant tumor-derived epitope in melanoma patients. J Immunol. 2007 Dec 01; 179(11):7932-40.
Score: 0.059
-
A mycoplasma peptide elicits heteroclitic CD4+ T cell responses against tumor antigen MAGE-A6. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6796-806.
Score: 0.059
-
Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro. J Immunother. 2007 Jan; 30(1):75-82.
Score: 0.056
-
Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers. J Immunol. 2006 Aug 15; 177(4):2717-27.
Score: 0.054
-
One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J Immunol. 2005 Feb 01; 174(3):1751-9.
Score: 0.049
-
MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. Clin Cancer Res. 2003 Mar; 9(3):947-54.
Score: 0.043
-
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. Oncoimmunology. 2021 03 26; 10(1):1898105.
Score: 0.037
-
Dysregulated NF-?B-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. Cancer Immunol Res. 2020 12; 8(12):1554-1567.
Score: 0.036
-
Impact of checkpoint blockade on cancer vaccine-activated CD8+ T cell responses. J Exp Med. 2020 07 06; 217(7).
Score: 0.035
-
Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci U S A. 2000 Jan 04; 97(1):400-5.
Score: 0.034
-
Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity. JCI Insight. 2017 09 21; 2(18).
Score: 0.029
-
PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8? T cells induced by melanoma vaccines. Cancer Res. 2014 Feb 15; 74(4):1045-55.
Score: 0.022
-
Focus on FOCIS: interleukin 2 treatment associated autoimmunity. Clin Immunol. 2008 May; 127(2):123-9.
Score: 0.015
-
Accumulation of low-avidity anti-melanocortin receptor 1 (anti-MC1R) CD8+ T cells in the lesional skin of a patient with melanoma-related depigmentation. Melanoma Res. 2006 Apr; 16(2):165-74.
Score: 0.013